NCT01180790 / 2010-022092-65: Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants |
|
|
| Completed | 2a | 122 | Europe, US | ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Peg-INF, Ribavirin, Ribasphere, Copegus | Alexion, Achillion, a wholly owned subsidiary of Alexion | Hepatitis C | 03/12 | 04/13 | | |
NCT01849562: Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants |
|
|
| Completed | 2a | 30 | NA | Sovaprevir, ACH-0141625, ACH-3102, Ribavirin, Placebo | Alexion, Achillion, a wholly owned subsidiary of Alexion | Hepatitis C, Chronic | 11/13 | 04/14 | | |